140 related articles for article (PubMed ID: 11554166)
21. Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells.
Koivunen J; Aaltonen V; Koskela S; Lehenkari P; Laato M; Peltonen J
Cancer Res; 2004 Aug; 64(16):5693-701. PubMed ID: 15313909
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of CA19-9 as a tumor marker in urothelial malignancy.
Chuang CK; Liao SK
Scand J Urol Nephrol; 2004; 38(5):359-65. PubMed ID: 15764245
[TBL] [Abstract][Full Text] [Related]
23. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
Zhou JT; Cai ZM; Li NC; Na YQ
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
[TBL] [Abstract][Full Text] [Related]
24. Protein kinase C eta is associated with progression of renal cell carcinoma (RCC).
Brenner W; Färber G; Herget T; Wiesner C; Hengstler JG; Thüroff JW
Anticancer Res; 2003; 23(5A):4001-6. PubMed ID: 14666709
[TBL] [Abstract][Full Text] [Related]
25. Expression of tissue transglutaminase in human bladder carcinoma.
Hager H; Jensen PH; Hamilton-Dutoit S; Neilsen MS; Birckbichler P; Gliemann J
J Pathol; 1997 Dec; 183(4):398-403. PubMed ID: 9496255
[TBL] [Abstract][Full Text] [Related]
26. The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway.
Uht RM; Amos S; Martin PM; Riggan AE; Hussaini IM
Oncogene; 2007 May; 26(20):2885-93. PubMed ID: 17146445
[TBL] [Abstract][Full Text] [Related]
27. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
[TBL] [Abstract][Full Text] [Related]
28. Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition.
Alkan S; Huang Q; Ergin M; Denning MF; Nand S; Maududi T; Paner GP; Ozpuyan F; Izban KF
Am J Hematol; 2005 Jun; 79(2):97-106. PubMed ID: 15929099
[TBL] [Abstract][Full Text] [Related]
29. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.
Yang CC; Chu KC; Yeh WM
Urol Oncol; 2004; 22(1):1-6. PubMed ID: 14969795
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the Na,K-ATPase alpha- and beta-subunit expression profiles of bladder cancer using tissue microarrays.
Espineda C; Seligson DB; James Ball W; Rao J; Palotie A; Horvath S; Huang Y; Shi T; Rajasekaran AK
Cancer; 2003 Apr; 97(8):1859-68. PubMed ID: 12673711
[TBL] [Abstract][Full Text] [Related]
31. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
32. Transient receptor potential vanilloid type 1 (TRPV1) expression changes from normal urothelium to transitional cell carcinoma of human bladder.
Lazzeri M; Vannucchi MG; Spinelli M; Bizzoco E; Beneforti P; Turini D; Faussone-Pellegrini MS
Eur Urol; 2005 Oct; 48(4):691-8. PubMed ID: 15992990
[TBL] [Abstract][Full Text] [Related]
33. [The significance of the expression of cyclooxygenase-2 in bladder transitional cell carcinoma tissues].
Ren L; Hou SK; He LF; Ye HY; Guan KP
Zhonghua Wai Ke Za Zhi; 2004 Sep; 42(18):1104-7. PubMed ID: 15498296
[TBL] [Abstract][Full Text] [Related]
34. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S
J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755
[TBL] [Abstract][Full Text] [Related]
35. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
[TBL] [Abstract][Full Text] [Related]
36. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
37. Deregulation of the cytoplasmic tyrosine kinase cSrc in the absence of a truncating mutation at codon 531 in human bladder carcinoma.
Bénistant C; Chapuis H; Mottet N; Noletti J; Crapez E; Bali JP; Roche S
Biochem Biophys Res Commun; 2000 Jul; 273(2):425-30. PubMed ID: 10873622
[TBL] [Abstract][Full Text] [Related]
38. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
[TBL] [Abstract][Full Text] [Related]
39. Involvement of protein kinase C in TNFalpha regulation of trabecular matrix metalloproteinases and TIMPs.
Alexander JP; Acott TS
Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):2831-8. PubMed ID: 11687525
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic significance of cathepsin B immunostaining in transitional neoplasia.
Visscher DW; Sloane BF; Sameni M; Babiarz JW; Jacobson J; Crissman JD
Mod Pathol; 1994 Jan; 7(1):76-81. PubMed ID: 8159656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
